Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a drug-related skin eruption following AstraZeneca-Oxford vaccination, which resolved after treatment with oral prednisolone.

This report discusses two cases where patients continued EGFR inhibitor therapy while receiving topical treatments for SDRIFE, highlighting the importance of dermatologists in managing such cutaneous adverse events without stopping cancer treatment.

This study found that the prevalence of dermatological manifestations in COVID-19 patients was 1.7% in Sri Lanka, with various types of skin lesions reported.

In this case report, researchers identified a potential adverse skin reaction, called SDRIFE or Baboon syndrome, caused by the drug tofacitinib in a 19-year-old woman being treated for alopecia subtotalis, leading the authors to recommend discontinuation of the drug.

This review summarizes literature and experiences on the skin manifestations in COVID-19 patients, suggesting some may help identify asymptomatic cases, but it reports no new clinical results.

This review discusses the distinctive non-infective skin presentations of HIV infection from a dermatological perspective and reports no new clinical findings.

This case study highlights that even short-term use of hydroxychloroquine for COVID-19 can potentially lead to acute generalized exanthematous pustulosis as an adverse effect.

This article reviews the identification and assessment of cutaneous drug reactions, emphasizing the importance of early recognition and the need for accurate diagnosis to prevent serious complications; it reports no new clinical results.

This review summarizes existing and new cases of generalized pustular psoriasis and acute generalized exanthematous pustulosis associated with COVID-19, noting that over half lacked a known drug trigger.

This report describes a case of acute localised exanthematous pustulosis in a 19-year-old boy after using amoxicillin-clavulanic acid, with new dermoscopic features identified.

Any drug can cause skin reactions, but antibiotics, NSAIDs, and psychotropic drugs are more common, with some reactions being life-threatening.

In this case study, a patient developed a rash consistent with acute generalized exanthematous pustulosis after increasing the dose of semaglutide, suggesting that the reaction was likely due to the excipient propylene glycol, highlighting the importance of ingredient analysis and multidisciplinary collaboration for patient safety.

This article discusses the impact of COVID-19 on skin health, highlighting various cutaneous manifestations and the need for dermatologists to adapt their practices during the pandemic, but it reports no new results.

This review examined dermatologic symptoms associated with COVID-19 in 2,560 patients, with chilblains/pernio-like lesions being the most common, suggesting these symptoms may aid in early identification of cases.

This review focuses on the various skin symptoms associated with COVID-19 but reports no new clinical findings.

This correspondence presents no new clinical findings about COVID-19 dermatological manifestations but references the Mexican Academy of Dermatology's COVID-19 registry.

This review discusses the range and management of adverse cutaneous reactions to psychotropic medications and emphasizes the need for awareness among clinicians, concluding with a call for careful monitoring and patient education.

In this case study, an 80-year-old woman developed lichen planus pigmentosus inversus after receiving multiple intra-articular injections of a homeopathic preparation, suggesting a possible link, though causality remains speculative.

This review discusses the complex pathophysiological and clinical aspects of COVID-19, including dermatological findings and their association with SARS-CoV-2 infection but reports no new clinical results.

Toxic shock syndrome is caused by a complex interaction of bacterial toxins and the immune system, and understanding this can help improve diagnosis and treatment.

This review discusses hypersensitivity reactions to anticoagulants, highlighting the importance of early diagnosis and exploring various diagnostic and management options, but it presents no new clinical findings.

This chapter discusses the mechanisms, presentation, course, differential diagnosis, and treatment of drug-induced skin reactions and reports no new clinical results.

This review suggests that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have potential benefits for dermatologic conditions but may also cause adverse skin reactions and impact surgical outcomes.

This review discusses mucocutaneous manifestations associated with Covid-19, classifies the lesions, and describes their characteristics and treatments but reports no new clinical findings.

Experts discussed treatments for skin conditions in children, emphasizing hydration, cautious medication use, and early intervention for infections.

This review discusses the cutaneous symptoms associated with COVID-19 and their potential use in diagnosing and assessing the severity of the disease, but it reports no new clinical results.

This review discusses the various skin lesions associated with COVID-19, which vary in type and severity, and reports that these lesions can appear before other symptoms and typically resolve spontaneously.

This review details various skin manifestations linked to COVID-19 and highlights dermatitides caused by personal protective equipment, emphasizing the need for accurate diagnosis and prompt treatment.

This study reports that cutaneous manifestations such as herpes zoster, purpura, and livedo reticularis in COVID-19 patients can potentially indicate disease severity, aiding in the prediction of the illness's progression and guiding dermatological management during the pandemic.

COVID-19 can cause various skin issues, including rashes and 'COVID toes', and may worsen autoimmune diseases or affect men with baldness more severely.